Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.63 |
| ▸ | POLA1 | P09884 | 1/20 | 0.62 |
| ▸ | OSBP | P22059 | 3/20 | 0.57 |
| ▸ | USP2 | O75604 | 2/20 | 0.57 |
| ▸ | RORC | P51449 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.57 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.57 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.54 |
| ▸ | NPC1L1 | Q9UHC9 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.52 |
| ▸ | GBA1 | P04062 | 2/20 | 0.51 |
| ▸ | UGCG | Q16739 | 2/20 | 0.51 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29194415 | 1.00 | CYP46A1 (0.63) | CYP46A1POLA1OSBPUSP2RORC | |
| SCHEMBL9277 | 1.00 | CYP46A1 (0.63) | CYP46A1POLA1OSBPUSP2RORC | |
| Hydrochloric Acid SCHEMBL18204490 | 0.95 | CYP46A1 (0.58) | CYP46A1POLA1OSBPUSP2RORC | |
| SCHEMBL6016758 | 0.93 | CYP46A1 (0.61) | CYP46A1POLA1OSBPUSP2RORC | |
| SCHEMBL6016760 | 0.93 | CYP46A1 (0.61) | CYP46A1POLA1OSBPUSP2RORC | |
| SCHEMBL6514439 | 0.93 | CYP46A1 (0.61) | CYP46A1POLA1OSBPUSP2RORC | |
| SCHEMBL5888344 | 0.90 | POLA1 (0.68) | CYP46A1POLA1OSBPUSP2RORC | |
| SCHEMBL5888346 | 0.90 | POLA1 (0.68) | CYP46A1POLA1OSBPUSP2RORC | |
| SCHEMBL23070074 | 0.88 | POLA1 (0.72) | CYP46A1POLA1OSBPUSP2RORC | |
| SCHEMBL10936315 | 0.88 | POLA1 (0.72) | CYP46A1POLA1OSBPUSP2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 23057 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4743490-A1 | HUMANIZED ANTI-CD7 ANTIBODY | Christian-Albrechts-Universität zu Kiel (DE) | 2026-05-20 | — | — | EP | claimed |
| WO-2026099502-A1 | NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2026-05-15 | — | — | WO | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-20260085100-A1 | METHODS OF ANTIGEN PRODUCTION | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2026-03-26 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| EP-4698185-A1 | METHODS AND SYSTEMS FOR IMPROVING ANTI-CANCER THERAPIES | Osasuna Therapeutics SA (CH) | 2026-02-25 | — | — | EP | claimed |
| EP-4694909-A1 | METHODS OF MODULATING THE EPITHELIAL-MESENCHYMAL TRANSITION | RS Oncology, LLC (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4687999-A1 | TROP2 CONJUGATED BIOLOGICAL MOLECULES, PHARMACEUTICAL COMPOSITIONS AND METHODS | OBI Pharma, Inc. (TW) | 2026-02-11 | — | — | EP | claimed |
| EP-4676544-A1 | ANTIBODY-DRUG CONJUGATE COMPRISING ANTIBODIES AGAINST HUMAN L1CAM AND USES THEREOF | LigaChem Biosciences Inc. (KR) | 2026-01-14 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-1999058126-B1 | USE OF NEOMYCIN FOR TREATING ANGIOGENESIS-RELATED DISEASES | ENDOWMENT RES INHUMAN BIOLOGY (US) | 2000-02-17 | — | — | WO | claimed |
| EP-0961612-A1 | PROTEIN STABILIZED PHARMACOLOGICALLY ACTIVE AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF | Vivorx Pharmaceuticals, Inc. (US) | 1999-12-08 | — | — | EP | claimed |
| WO-1999058126-A1 | USE OF NEOMYCIN FOR TREATING ANGIOGENESIS-RELATED DISEASES | THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. (US) | 1999-11-18 | — | — | WO | claimed |
| WO-1999055314-A1 | FIBRINOGEN COATED DROPLETS OF LIQUID HYDROPHOBIC PHASES | UNIVERSITY OF CINCINNATI (US) | 1999-11-04 | — | — | WO | claimed |
| WO-1999042578-A2 | MODULATION OF CELL PROLIFERATION, METHODS AND REAGENTS | COLD SPRING HARBOR LABORATORY (US) | 1999-08-26 | — | — | WO | claimed |
| US-5916596-A | WATER INSOLUBLE DRUGS AND DRUG DELIVERY | VIVORX PHARMACEUTICALS, INC. (US) | 1999-06-29 | — | — | US | claimed |
| WO-1998014174-A1 | PROTEIN STABILIZED PHARMACOLOGICALLY ACTIVE AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF | VIVORX PHARMACEUTICALS, INC. (US) | 1998-04-09 | — | — | WO | claimed |
| US-5560933-A | INCLUDES BIOCOMPATIBLE POLYMER CAPABLE OF BEING CROSSLINKED BY DISULFIDE BONDS TO PRODUCE SHELL | VIVORX PHARMACEUTICALS, INC. (US) | 1996-10-01 | — | — | US | claimed |
| US-5439686-A | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor | VIVORX PHARMACEUTICALS, INC. (US) | 1995-08-08 | — | — | US | claimed |